Enlivex Therapeutics (Enlivex Therapeutics) Short-Term Debt : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Short-Term Debt?

Enlivex Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

Enlivex Therapeutics Short-Term Debt Historical Data

The historical data trend for Enlivex Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Short-Term Debt Chart

Enlivex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Enlivex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Enlivex Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Enlivex Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.